Headlines about Bruker Corporation (NASDAQ:BRKR) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bruker Corporation earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.4394845903163 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of research analysts recently issued reports on BRKR shares. Deutsche Bank AG boosted their target price on shares of Bruker Corporation from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Monday, May 15th. BidaskClub downgraded shares of Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Barclays PLC reiterated an “equal weight” rating and set a $30.00 target price (up previously from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Cowen and Company reiterated a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a research report on Friday, July 14th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $29.00 target price on shares of Bruker Corporation in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $27.00.

Shares of Bruker Corporation (NASDAQ BRKR) opened at 29.11 on Friday. Bruker Corporation has a one year low of $19.59 and a one year high of $30.22. The stock has a market cap of $4.62 billion, a P/E ratio of 29.02 and a beta of 1.10. The stock has a 50 day moving average of $28.30 and a 200 day moving average of $26.13.

Bruker Corporation (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03. The firm had revenue of $414.90 million during the quarter, compared to analyst estimates of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. Bruker Corporation’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.20 EPS. On average, analysts forecast that Bruker Corporation will post $1.12 EPS for the current year.

Bruker Corporation declared that its board has initiated a stock repurchase program on Friday, May 12th that authorizes the company to repurchase $225.00 million in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th will be given a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 31st. Bruker Corporation’s dividend payout ratio is presently 16.00%.

In other news, Director Ingen Chris Van sold 19,900 shares of Bruker Corporation stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $28.03, for a total value of $557,797.00. Following the completion of the transaction, the director now owns 14,577 shares of the company’s stock, valued at approximately $408,593.31. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Frank H. Laukien bought 2,335 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $27.39 per share, with a total value of $63,955.65. Following the transaction, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 117,624 shares of company stock valued at $3,271,574. 35.20% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/bruker-corporation-brkr-earning-somewhat-positive-news-coverage-study-shows/1539196.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.